Integrated Management Strategies for Hypertension and Diabetes in Cardiovascular Disease Prevention: A Systematic...

Type 2 diabetes and hypertension frequently coexist and substantially elevate the risk of cardiovascular complications due to interconnected metabolic and vascular mechanisms. The combined presence of these conditions accelerates atherosclerosis, endothelial dysfunction, and inflammatory processes, leading to an increased incidence of adverse cardiovascular events. Existing literature primarily emphasizes individual therapeutic interventions, while limited evidence explores the combined impact of pharmacological treatments and system-level strategies in real-world clinical settings. This study evaluates evidence on therapeutic approaches and integrated care models in relation to cardiovascular outcomes among affected populations. A systematic review with narrative synthesis was conducted without meta-analysis, incorporating 10 studies identified through structured database searches, screened according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, and evaluated using the Newcastle-Ottawa Scale where appropriate. Across the included studies, evidence clustered around three main themes: pharmacological cardioprotection, cardiometabolic risk-factor stability, and integrated care delivery. The findings indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists were associated with more favorable cardiovascular profiles compared to conventional glucose-lowering therapies. Stable glycemic control and reduced hemoglobin A1c (HbA1c) variability were consistently associated with improved cardiovascular outcomes. Hypertension-related findings showed that SGLT2 inhibitors were associated with a lower risk of incident hypertension compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, while multifactorial risk-factor control involving blood pressure, glycemia, lipid parameters, and smoking reduction was associated with fewer cardiovascular events. At the care-delivery level, integrated care frameworks, including HEARTS-aligned approaches, may support healthcare delivery through standardized protocols, multidisciplinary coordination, and continuous monitoring; however, protocol-level HEARTS evidence should be interpreted as implementation-planning evidence rather than proof of improved cardiovascular outcomes. These observations reinforce the importance of adopting a comprehensive, patient-centered approach that integrates both therapeutic advancements and structured healthcare systems for optimal disease management.